Inclisiran
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease
Trial Timeline
Jun 25, 2021 → Sep 15, 2023
NCT ID
NCT04929249About Inclisiran
Inclisiran is a phase 3 stage product being developed by Novartis for Atherosclerotic Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04929249. Target conditions include Atherosclerotic Cardiovascular Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06249165 | Approved | Active |
| NCT06386419 | Approved | Active |
| NCT05682378 | Phase 3 | Active |
| NCT04929249 | Phase 3 | Completed |
| NCT04873934 | Phase 3 | Completed |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease